The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.
about
The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinibImmune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With ImmunotherapyCombined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib.Identifying the structure-activity relationship of leelamine necessary for inhibiting intracellular cholesterol transport.Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib.BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaThe outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trialExtrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastasesDabrafenib in metastatic melanoma: a monocentric 'real life' experience.Of Mice and Melanoma: PDX System for Modeling Personalized Medicine.Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progressionDependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition.Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib.Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.Immune checkpoint inhibitors in melanoma
P2860
Q26744335-36D49223-1FCE-47B0-9956-A4AF7BD4A037Q26796309-5126BEA8-E391-4B2E-99EC-E5FF0EA8DFBBQ33433902-26B325AA-31C8-44E5-91D4-AB246C775A4CQ33709666-F0804303-252A-45E2-9D55-8C80EFEC6A8CQ33882096-ECADF6A9-B24B-4CAC-B77F-CA595F1A70FAQ34667825-677A0CA7-5742-4AC6-91DD-F7D373D25DEBQ34786402-D42217FC-68CF-4A9F-BB70-3402B20B7C61Q36243993-B69DE6F2-D557-4342-AA6B-03A451851E06Q36533041-01FF7133-D618-44A7-945D-C047B2433069Q36652790-5A6C93E1-A2C6-4BE6-8375-52824FD86FCBQ36759429-B1727F49-2BC0-456F-BB8E-F06A26FF3D87Q37381163-26DD6114-7266-4848-9E62-1598195C4768Q37644414-1D6B8038-ED7F-4FAF-861B-FDE750A1752BQ47163375-B46B05DD-81AD-485D-8F2A-7C34C625F6E3Q47268734-E03789B9-4E20-42D4-81D2-0C354912EEE8Q47325071-C08C36A2-608C-40A3-B32A-202B9DE2FB70Q47653459-649C34B1-31AF-4E74-A243-BB75322B27E2Q48523042-8847D14D-89D8-43FE-A1B4-FF89192581C4Q51000664-C07A8E5A-909C-470F-AF8C-4C12E8D51610Q56895914-A29654EF-2233-4C35-A3CC-2D6D0FAC8041
P2860
The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The nature and management of m ...... s of extended BRAF inhibition.
@ast
The nature and management of m ...... s of extended BRAF inhibition.
@en
The nature and management of m ...... s of extended BRAF inhibition.
@nl
type
label
The nature and management of m ...... s of extended BRAF inhibition.
@ast
The nature and management of m ...... s of extended BRAF inhibition.
@en
The nature and management of m ...... s of extended BRAF inhibition.
@nl
prefLabel
The nature and management of m ...... s of extended BRAF inhibition.
@ast
The nature and management of m ...... s of extended BRAF inhibition.
@en
The nature and management of m ...... s of extended BRAF inhibition.
@nl
P2093
P2860
P50
P356
P1433
P1476
The nature and management of m ...... ts of extended BRAF inhibition
@en
P2093
Alexander Guminski
Arthur Clements
Lauren E Haydu
Mary W F Azer
Matthew M K Chan
Megan Lyle
Oliver Klein
P2860
P304
P356
10.1002/CNCR.28851
P407
P577
2014-07-01T00:00:00Z